The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.
Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion
Open accessAbstract
SUMMARY FTO, an RNA N6-methyladenosine (m6A) demethylase, plays oncogenic roles in various cancers, presenting an opportunity for the development of effective targeted therapeutics. Here we report two potent small-molecule FTO inhibitors that exhibit strong anti-tumor effects in multiple types of cancers. We show that genetic depletion and pharmacological inhibition of FTO dramatically attenuate leukemia stem/initiating cell self-renewal and reprogram immune response by suppressing expression of immune checkpoint genes, especially LILRB4. FTO inhibition sensitizes leukemia cells to T cell cytotoxicity and overcomes hypomethylating agent-induced immune evasion. Our study demonstrates that FTO plays critical roles in cancer stem cell self-renewal and immune evasion, and highlights the broad potential of targeting FTO for cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Friesner, R. A., Banks, J. L., Murphy, R. B., Halgren, T. A., Klicic, J. J., Mainz, D. T., Repasky, M. P., Knoll, E. H., Shelley, M., Perry, J. K., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0306430 · Cited by 10,057
Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration
Thorvaldsdottir, H., Robinson, J. T., & Mesirov, J. P. (2013) · Briefings in Bioinformatics · doi:10.1093/bib/bbs017 · Cited by 9,049
Lead- and drug-like compounds: the rule-of-five revolution
Lipinski, C. A. (2004) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2004.11.007 · Cited by 6,199
Improved vectors and genome-wide libraries for CRISPR screening
Sanjana, N. E., Shalem, O., & Zhang, F. (2014) · Nature Methods · doi:10.1038/nmeth.3047 · Cited by 5,239
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812 · cited 1×
“Monoclonal antibodies targeting the PD-1/PD-L1/PD-L2 axis have achieved encouraging effects in clinical practice in treating multiple types of solid tumors (Gopalakrishnan et al., 2018; Patnaik et al., 2015; Topalian et al., 2012), but demonstrated only limited effects in AML (Berger et al.”
N6-methyladenosine-dependent regulation of messenger RNA stability
Wang, X., Lu, Z., Gomez, A., Hon, G. C., Yue, Y., Han, D., Fu, Y., Parisien, M., Dai, Q., Jia, G., et al. (2014) · Nature · doi:10.1038/nature12730 · Cited by 4,558
N6-Methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO
Jia, G., Fu, Y., Zhao, X., Dai, Q., Zheng, G., Yang, Y., Yi, C., Lindahl, T., Pan, T., Yang, Y.-G., et al. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.687 · Cited by 4,106
Baell, J. B., & Holloway, G. A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901137j · Cited by 3,944
ALKBH5 Is a Mammalian RNA Demethylase that Impacts RNA Metabolism and Mouse Fertility
Zheng, G., Dahl, J. A., Niu, Y., Fedorcsak, P., Huang, C.-M., Li, C. J., Vågbø, C. B., Shi, Y., Wang, W.-L., Song, S.-H., et al. (2013) · Molecular Cell · doi:10.1016/j.molcel.2012.10.015 · Cited by 3,550
Self-citationA Third-Generation Lentivirus Vector with a Conditional Packaging System
Dull, T., Zufferey, R., Kelly, M., Mandel, R. J., Nguyen, M., Trono, D., & Naldini, L. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8463-8471.1998 · Cited by 3,341
Hu, Y., & Smyth, G. K. (2009) · Journal of Immunological Methods · doi:10.1016/j.jim.2009.06.008 · Cited by 2,083
MODOMICS: a database of RNA modification pathways. 2017 update
Boccaletto, P., Machnicka, M. A., Purta, E., Piątkowski, P., Bagiński, B., Wirecki, T. K., de Crécy-Lagard, V., Ross, R., Limbach, P. A., Kotter, A., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1030 · Cited by 1,782
Lentivirus-delivered stable gene silencing by RNAi in primary cells
STEWART, S. A., DYKXHOORN, D. M., PALLISER, D., MIZUNO, H., YU, E. Y., AN, D. S., SABATINI, D. M., CHEN, I. S. Y., HAHN, W. C., SHARP, P. A., et al. (2003) · RNA · doi:10.1261/rna.2192803 · Cited by 1,582
Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9
Krivtsov, A. V., Twomey, D., Feng, Z., Stubbs, M. C., Wang, Y., Faber, J., Levine, J. E., Wang, J., Hahn, W. C., Gilliland, D. G., et al. (2006) · Nature · doi:10.1038/nature04980 · Cited by 1,513 · cited 1×
“To test this, we conducted in vitro and in vivo limiting dilution assays (Krivtsov et al., 2006; Li et al., 2015; Weng et al., 2018).”
FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N 6 -Methyladenosine RNA Demethylase
Li, Z., Weng, H., Su, R., Weng, X., Zuo, Z., Li, C., Huang, H., Nachtergaele, S., Dong, L., Hu, C., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2016.11.017 · Cited by 1,508
Self-citationThe cellular thermal shift assay for evaluating drug target interactions in cells
Jafari, R., Almqvist, H., Axelsson, H., Ignatushchenko, M., Lundbäck, T., Nordlund, P., & Molina, D. M. (2014) · Nature Protocols · doi:10.1038/nprot.2014.138 · Cited by 1,474
RNA modifications modulate gene expression during development
Frye, M., Harada, B. T., Behm, M., & He, C. (2018) · Science · doi:10.1126/science.aau1646 · Cited by 1,249
Vu, L. P., Pickering, B. F., Cheng, Y., Zaccara, S., Nguyen, D., Minuesa, G., Chou, T., Chow, A., Saletore, Y., MacKay, M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4416 · Cited by 1,237
m6A Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer
Huang, H., Weng, H., & Chen, J. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.02.004 · Cited by 1,226
Self-citationDombret, H., Seymour, J. F., Butrym, A., Wierzbowska, A., Selleslag, D., Jang, J. H., Kumar, R., Cavenagh, J., Schuh, A. C., Candoni, A., et al. (2015) · Blood · doi:10.1182/blood-2015-01-621664 · Cited by 1,165
R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m6A/MYC/CEBPA Signaling
Su, R., Dong, L., Li, C., Nachtergaele, S., Wunderlich, M., Qing, Y., Deng, X., Wang, Y., Weng, X., Hu, C., et al. (2018) · Cell · doi:10.1016/j.cell.2017.11.031 · Cited by 1,137 · cited 14×
“Western blot assay was performed as described previously (Su et al., 2018).”
InfluentialSelf-citationTarget identification using drug affinity responsive target stability (DARTS)
Lomenick, B., Hao, R., Jonai, N., Chin, R. M., Aghajan, M., Warburton, S., Wang, J., Wu, R. P., Gomez, F., Loo, J. A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910040106 · Cited by 1,095
Promoter-bound METTL3 maintains myeloid leukaemia by m6A-dependent translation control
Barbieri, I., Tzelepis, K., Pandolfini, L., Shi, J., Millán-Zambrano, G., Robson, S. C., Aspris, D., Migliori, V., Bannister, A. J., Han, N., et al. (2017) · Nature · doi:10.1038/nature24678 · Cited by 1,086
Immune Escape Mechanisms as a Guide for Cancer Immunotherapy
Beatty, G. L., & Gladney, W. L. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1860 · Cited by 1,078
Weng, H., Huang, H., Wu, H., Qin, X., Zhao, B. S., Dong, L., Shi, H., Skibbe, J., Shen, C., Hu, C., et al. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2017.11.016 · Cited by 968
Self-citationA Versatile Viral System for Expression and Depletion of Proteins in Mammalian Cells
Campeau, E., Ruhl, V. E., Rodier, F., Smith, C. L., Rahmberg, B. L., Fuss, J. O., Campisi, J., Yaswen, P., Cooper, P. K., & Kaufman, P. D. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006529 · Cited by 964
Anti-tumour immunity controlled through mRNA m6A methylation and YTHDF1 in dendritic cells
Han, D., Liu, J., Chen, C., Dong, L., Liu, Y., Chang, R., Huang, X., Liu, Y., Wang, J., Dougherty, U., et al. (2019) · Nature · doi:10.1038/s41586-019-0916-x · Cited by 955
Self-citationSmall-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia
Huang, Y., Su, R., Sheng, Y., Dong, L., Dong, Z., Xu, H., Ni, T., Zhang, Z. S., Zhang, T., Li, C., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.03.006 · Cited by 877
Self-citationRNA N6-methyladenosine modification in cancers: current status and perspectives
Deng, X., Su, R., Weng, H., Huang, H., Li, Z., & Chen, J. (2018) · Cell Research · doi:10.1038/s41422-018-0034-6 · Cited by 845
Self-citationIssa, J.-P. J., Garcia-Manero, G., Giles, F. J., Mannari, R., Thomas, D., Faderl, S., Bayar, E., Lyons, J., Rosenfeld, C. S., Cortes, J., et al. (2004) · Blood · doi:10.1182/blood-2003-03-0687 · Cited by 809
Patnaik, A., Kang, S. P., Rasco, D., Papadopoulos, K. P., Elassaiss-Schaap, J., Beeram, M., Drengler, R., Chen, C., Smith, L., Espino, G., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2607 · Cited by 807
Differential m6A, m6Am, and m1A Demethylation Mediated by FTO in the Cell Nucleus and Cytoplasm
Wei, J., Liu, F., Lu, Z., Fei, Q., Ai, Y., He, P. C., Shi, H., Cui, X., Su, R., Klungland, A., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.08.011 · Cited by 783
Self-citationm6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade
Yang, S., Wei, J., Cui, Y.-H., Park, G., Shah, P., Deng, Y., Aplin, A. E., Lu, Z., Hwang, S., He, C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10669-0 · Cited by 743
Yang, H., Bueso-Ramos, C., DiNardo, C., Estecio, M. R., Davanlou, M., Geng, Q.-R., Fang, Z., Nguyen, M., Pierce, S., Wei, Y., et al. (2014) · Leukemia · doi:10.1038/leu.2013.355 · Cited by 688
Berger, R., Rotem-Yehudar, R., Slama, G., Landes, S., Kneller, A., Leiba, M., Koren-Michowitz, M., Shimoni, A., & Nagler, A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4079 · Cited by 680
Meclofenamic acid selectively inhibits FTO demethylation of m6A over ALKBH5
Huang, Y., Yan, J., Li, Q., Li, J., Gong, S., Zhou, H., Gan, J., Jiang, H., Jia, G.-F., Luo, C., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1276 · Cited by 662
Self-citationRNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3
Niu, Y., Lin, Z., Wan, A., Chen, H., Liang, H., Sun, L., Wang, Y., Li, X., Xiong, X.-F., Wei, B., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1004-4 · Cited by 593
Self-citationDaver, N., Garcia-Manero, G., Basu, S., Boddu, P. C., Alfayez, M., Cortes, J. E., Konopleva, M., Ravandi-Kashani, F., Jabbour, E., Kadia, T., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0774 · Cited by 555
Cyclodextrin-based controlled drug release system
Hirayama, F. (1999) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(98)00058-1 · Cited by 494
Development of Cell-Active N6-Methyladenosine RNA Demethylase FTO Inhibitor
Chen, B., Ye, F., Yu, L., Jia, G., Huang, X., Zhang, X., Peng, S., Chen, K., Wang, M., Gong, S., et al. (2012) · Journal of the American Chemical Society · doi:10.1021/ja3064149 · Cited by 444
Self-citationReversible RNA adenosine methylation in biological regulation
Jia, G., Fu, Y., & He, C. (2013) · Trends in Genetics · doi:10.1016/j.tig.2012.11.003 · Cited by 424
LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration
Deng, M., Gui, X., Kim, J., Xie, L., Chen, W., Li, Z., He, L., Chen, Y., Chen, H., Luo, W., et al. (2018) · Nature · doi:10.1038/s41586-018-0615-z · Cited by 305
Self-citationTherapeutic targeting of acute myeloid leukemia stem cells
Pollyea, D. A., & Jordan, C. T. (2017) · Blood · doi:10.1182/blood-2016-10-696039 · Cited by 299
FTO controls reversible m6Am RNA methylation during snRNA biogenesis
Mauer, J., Sindelar, M., Despic, V., Guez, T., Hawley, B. R., Vasseur, J.-J., Rentmeister, A., Gross, S. S., Pellizzoni, L., Debart, F., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0231-8 · Cited by 268
Chen, H.-M., van der Touw, W., Wang, Y. S., Kang, K., Mai, S., Zhang, J., Alsina-Beauchamp, D., Duty, J. A., Mungamuri, S. K., Zhang, B., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97570 · Cited by 253
Self-citationStructural insights into FTO’s catalytic mechanism for the demethylation of multiple RNA substrates
Zhang, X., Wei, L.-H., Wang, Y., Xiao, Y., Liu, J., Zhang, W., Yan, N., Amu, G., Tang, X., Zhang, L., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1820574116 · Cited by 237
Li, L., Osdal, T., Ho, Y., Chun, S., McDonald, T., Agarwal, P., Lin, A., Chu, S., Qi, J., Li, L., et al. (2014) · Cell stem cell · doi:10.1016/j.stem.2014.08.001 · Cited by 234
Self-citationHuth, J. R., Mendoza, R., Olejniczak, E. T., Johnson, R. W., Cothron, D. A., Liu, Y., Lerner, C. G., Chen, J., & Hajduk, P. J. (2005) · Journal of the American Chemical Society · doi:10.1021/ja0455547 · Cited by 228
Self-citationKang, X., Kim, J., Deng, M., John, S., Chen, H., Wu, G., Phan, H., & Zhang, C. C. (2016) · Cell Cycle · doi:10.1080/15384101.2015.1121324 · Cited by 206
Role of N6-methyladenosine modification in cancer
Deng, X., Su, R., Feng, X., Wei, M., & Chen, J. (2018) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2017.10.005 · Cited by 200
Self-citationØrskov, A. D., Treppendahl, M. B., Skovbo, A., Holm, M. S., Friis, L. S., Hokland, M., & Grønbæk, K. (2015) · Oncotarget · doi:10.18632/oncotarget.3324 · Cited by 188
PEG- b -PLA micelles and PLGA- b -PEG- b -PLGA sol–gels for drug delivery
Cho, H., Gao, J., & Kwon, G. S. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.12.015 · Cited by 186
Production and Titration of Lentiviral Vectors
Salmon, P., & Trono, D. (2007) · Current Protocols in Human Genetics · doi:10.1002/0471142905.hg1210s54 · Cited by 185
Right on target: eradicating leukemic stem cells
Krause, D. S., & Etten, R. A. V. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.09.003 · Cited by 150
Wang, T., Hong, T., Huang, Y., Su, H., Wu, F., Chen, Y., Wei, L., Huang, W., Hua, X., Yu, X., et al. (2015) · Journal of the American Chemical Society · doi:10.1021/jacs.5b06690 · Cited by 145
Self-citationSingh, B., Kinne, H. E., Milligan, R. D., Washburn, L. J., Olsen, M. J., & Lucci, A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0159072 · Cited by 138
Self-citationSynthesis of a FTO Inhibitor with Anticonvulsant Activity
Zheng, G., Cox, T., Tribbey, L., Wang, G. Z., Iacoban, P., Booher, M. E., Gabriel, G. J., Zhou, L., Bae, N. S., Rowles, J., et al. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500042t · Cited by 133
Self-citationToh, J. D. W., Sun, L., Lau, L. Z. M., Tan, J., Low, J. J. A., Tang, C. W. Q., Cheong, E. J. Y., Tan, M. J. H., Chen, Y., Hong, W., et al. (2014) · Chemical Science · doi:10.1039/c4sc02554g · Cited by 127
AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model
Wunderlich, M., Mizukawa, B. E., Chou, F., Sexton, C., Shrestha, M., Saunthararajah, Y., & Mulloy, J. C. (2013) · Blood · doi:10.1182/blood-2012-10-464677 · Cited by 124
Self-citationHematopoietic Differentiation Is Required for Initiation of Acute Myeloid Leukemia
Ye, M., Zhang, H., Yang, H. H., Koche, R. P., Staber, P. B., Cusan, M., Levantini, E., Welner, R. S., Bach, C., Zhang, J., et al. (2015) · Cell stem cell · doi:10.1016/j.stem.2015.08.011 · Cited by 120
He, W., Zhou, B., Liu, W., Zhang, M., Shen, Z., Han, Z., Jiang, Q., Yang, Q., Song, C., Wang, R., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00702 · Cited by 119
Overexpression and knockout of miR-126 both promote leukemogenesis
Li, Z., Chen, P., Su, R. J., Li, Y., Hu, C., Wang, Y., Arnovitz, S., He, M., Gurbuxani, S. K., Zuo, Z., et al. (2015) · Blood · doi:10.1182/blood-2015-04-639062 · Cited by 112
Self-citationZhang, Y., Chen, H.-X., Zhou, S., Wang, S., Zheng, K., Xu, D., Liu, Y., Wang, X., Wang, X., Yan, H., et al. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0326-0 · Cited by 110
Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: Novel Combinations and Therapeutic Targets
Stahl, M. F., & Goldberg, A. D. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0781-7 · Cited by 109
RNA Modifications in Cancer: Functions, Mechanisms, and Therapeutic Implications
Huang, H., Weng, H., Deng, X., & Chen, J. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033357 · Cited by 92
Self-citationA Selective Small Molecule DNA2 Inhibitor for Sensitization of Human Cancer Cells to Chemotherapy
Liu, W., Zhou, M., Li, Z., Li, H., Polaczek, P., Dai, H., Wu, Q., Liu, C., Karanja, K. K., Popuri, V., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.02.043 · Cited by 91
Self-citationTang, X., Liu, S., Chen, D., Zhao, Z., & Zhou, J. (2018) · Oncology Letters · doi:10.3892/ol.2018.9873 · Cited by 74
Self-citationYun, S., Vincelette, N. D., Abraham, I. L., Robertson, K. D., Fernández-Zapico, M. E., & Patnaik, M. M. (2016) · Clinical Epigenetics · doi:10.1186/s13148-016-0233-2 · Cited by 70
Initiation of MLL-rearranged AML is dependent on C/EBPα
Ohlsson, E., Hasemann, M. S., Willer, A., Lauridsen, F. K. B., Rapin, N., Jendholm, J., & Porse, B. T. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20130932 · Cited by 67
Peters, G. J., Kraal, I., & Pinedo, H. M. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.46 · Cited by 53
Phase I study of Brequinar sodium (NSC 368390) in patients with solid malignancies
Schwartsmann, G., Dodion, P. F., Vermorken, J. B., Huinink, W. W. T. B., Joggi, J., Winograd, B., Gall, H. E., Simonetti, G., van der Vijgh, W. J. F., van Hennik, M. B., et al. (1990) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00686235 · Cited by 47
Stereoselective Stabilization of Polymeric Vitamin E Conjugate Micelles
Gao, M., Deng, J., Chu, H., Tang, Y. P., Wang, Z., Zhao, Y., & Li, G. (2017) · Biomacromolecules · doi:10.1021/acs.biomac.7b01409 · Cited by 43
Self-citationPhase I and pharmacokinetic study of brequinar sodium (NSC 368390).
Noe, D. A., Rowinsky, E. K., Shen, H. S., Clarke, B., Grochow, L. B., McGuire, W. P., Hantel, A., Adams, D. B., Abeloff, M. D., & Ettinger, D. S. (1990) · PubMed · Cited by 42
Padariya, M., & Kalathiya, U. (2016) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2016.09.008 · Cited by 31
Burris, H. A., Raymond, É., Awada, A. H., Kuhn, J. G., O’Rourke, T. J., Brentzel, J., Lynch, W., King, S. P., Brown, T. D., & Hoff, D. D. V. (1998) · Investigational New Drugs · doi:10.1023/a:1016066529642 · Cited by 27
Checkpoint inhibitors and acute myelogenous leukemia: promises and challenges
Alfayez, M., & Borthakur, G. M. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1459184 · Cited by 27
Cited by
The role of m6A modification in the biological functions and diseases
Jiang, X., Liu, B., Nie, Z., Duan, L., Xiong, Q., Jin, Z., Yang, C., & Chen, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00450-x · Cited by 2,335
The role of m6A RNA methylation in cancer metabolism
An, Y., & Duan, H. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01500-4 · Cited by 871
Xiong, J., He, J., Zhu, J., Pan, J., Liao, W., Ye, H., Wang, H., Song, Y., Du, Y., Cui, B., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.02.033 · Cited by 804
The hallmarks of cancer immune evasion
Galassi, C., Chan, T. A., Vitale, I., & Galluzzi, L. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.09.010 · Cited by 565
Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets
Yang, J., Xu, J., Wang, W., Zhang, B., Yu, X., & Shi, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01480-x · Cited by 388
Self-citation
Metadata
- Authors
- Su, R., Dong, L., Li, Y., Gao, M., Han, L., Wunderlich, M., Deng, X., Li, H., Huang, Y., Gao, L., Li, C., Zhao, Z., Robinson, S., Tan, B., Qing, Y., Qin, X., Prince, E., Xie, J., Qin, H., Li, W., Shen, C., Sun, J., Kulkarni, P., Weng, H., Huang, H., Chen, Z., Zhang, B., Wu, X., Olsen, M. J., Müschen, M., Marcucci, G., Salgia, R., Li, L., Fathi, A. T., Li, Z., Mulloy, J. C., Wei, M., Horne, D., & Chen, J.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2020-07
- Volume
- 38
- Issue
- 1
- Pages
- 79-96.e11
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W3034923646
- Cited by
- 763
- References
- 84
- FWCI
- 28.08
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.